Original Article

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

Richard G. Langley, M.D., Boni E. Elewski, M.D., Mark Lebwohl, M.D., Kristian Reich, M.D., Ph.D., Christopher E.M. Griffiths, M.D., Kim Papp, M.D., Ph.D., Lluís Puig, M.D., Ph.D., Hidemi Nakagawa, M.D., Ph.D., Lynda Spelman, M.B., B.S., Bárður Sigurgeirsson, M.D., Ph.D., Enrique Rivas, M.D., Tsen-Fang Tsai, M.D.,

Norman Wasel, M.D., Stephen Tyring, M.D., Ph.D., Thomas Salko, B.A., Isabelle Hampele, Ph.D., Marianne Notter, M.S., Alexander Karpov, Ph.D., Silvia Helou, M.D.,

Ph.D., Charis Papavassilis, M.D., Ph.D., for the ERASURE and FIXTURE Study Groups

N Engl J MedVolume 371(4):326-338

July 24, 2014

Study Overview

• In two trials in patients with moderate-to-severe plaque psoriasis, the anti–interleukin-17A monoclonal antibody secukinumab was more effective than placebo and etanercept.

• Infectious complications occurred more often with secukinumab than with placebo.

Speed of Response.

Langley RG et al. N Engl J Med 2014;371:326-338

Efficacy over Time.

Langley RG et al. N Engl J Med 2014;371:326-338

Demographic and Baseline Clinical Characteristics of the Patients.

Langley RG et al. N Engl J Med 2014;371:326-338

Efficacy End Points in ERASURE.

Langley RG et al. N Engl J Med 2014;371:326-338

Efficacy End Points in FIXTURE.

Langley RG et al. N Engl J Med 2014;371:326-338

Adverse Events during the Induction Period and the Entire 52-Week Study Period in FIXTURE.

Langley RG et al. N Engl J Med 2014;371:326-338

Conclusions

• Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target.